The IMPROVE™ study: converting from human premix to NovoLog® Mix 70/30 (insulin cohort)3
Results from patients who completed the IMPROVE™ study who were previously treated with human premix ± OAD therapy and had A1C values available at baseline and final visit. The IMPROVE study is a multinational, open-label, nonrandomized, 26-week, observational study evaluating the safety and efficacy of NovoLog® Mix 70/30 in patients with type 2 diabetes.3
The 1-2-3 study:
1, 2, and 3 daily doses: reaching A1C goal with NovoLog® Mix 70/30
In a separate study, one, two, and three daily doses helped the majority of patients get to A1C goal of <7%. A once-daily dose at dinner helped 41% of patients achieve A1C goal, an additional dose at breakfast helped 70% of patients achieve A1C goal, and an additional third dose at lunchtime helped 77% of patients achieve A1C goal.4
A 48-week, open-label, observational study in 100 patients 18 years and older with type 2 diabetes for 12 months and A1C levels between 7.5% and 10%. Patients had been previously treated on a stable antidiabetic regimen for at least 3 months. NovoLog® Mix 70/30 was initiated once daily during phase 1 and titrated in phases to dosing schedules of BID (phase 2) and TID (phase 3) as needed to reach treatment goals. Subjects achieving an A1C level of 6.5% were considered to have completed the study. Patients not achieving an A1C level of 6.5% continued to phase 3. Results include phases 1, 2, and 3.4
Each time the dosing schedule was titrated, NovoLog® Mix 70/30 provided additional benefits without an increase in major hypoglycemia.4
Along with A1C reductions, see how PPG and FPG improvements were observed when converting to NovoLog® Mix 70/30.5,6
